191 related articles for article (PubMed ID: 21040579)
1. Radioiodine thyroid remnant ablation in patients with differentiated thyroid carcinoma (DTC): prospective comparison of long-term outcomes of treatment with 30, 60 and 100 mCi.
Kukulska A; Krajewska J; Gawkowska-Suwińska M; Puch Z; Paliczka-Cieslik E; Roskosz J; Handkiewicz-Junak D; Jarzab M; Gubała E; Jarzab B
Thyroid Res; 2010 Nov; 3(1):9. PubMed ID: 21040579
[TBL] [Abstract][Full Text] [Related]
2. [Optimization of 131I ablation in patients with differentiated thyroid carcinoma: comparison of early outcomes of treatment with 100 mCi versus 60 mCi].
Kukulska A; Krajewska J; Roskosz J; Handkiewicz-Junak D; Jarzab M; Paliczka E; Puch Z; Wygoda Z; Gubała E; Jarzab B
Endokrynol Pol; 2006; 57(4):374-9. PubMed ID: 17006839
[TBL] [Abstract][Full Text] [Related]
3. Lithium as an adjuvant in the postoperative ablation of remnant tissue in low-risk thyroid carcinoma.
Yamazaki CA; Padovani RP; Biscolla RP; Ikejiri ES; Marchetti RR; Castiglioni ML; Matsumura LK; Maciel RM; Furlanetto RP
Thyroid; 2012 Oct; 22(10):1002-6. PubMed ID: 22953991
[TBL] [Abstract][Full Text] [Related]
4. Thyroid remnant 131I ablation for papillary and follicular thyroid carcinoma.
Mazzaferri EL
Thyroid; 1997 Apr; 7(2):265-71. PubMed ID: 9133698
[TBL] [Abstract][Full Text] [Related]
5. Thyroid remnant ablation with radioiodine activity of 30, 60, and 100 mCi in patients with differentiated thyroid cancer - a prospective comparison of long-term outcomes.
Kukulska A; Krajewska J; Gawkowska M; Paliczka-Cieslik E; Handkiewicz-Junak D; Kropińska A; Puch Z; Olczyk T; Roskosz J; Jarzab B
Arch Med Sci; 2022; 18(5):1241-1247. PubMed ID: 36160333
[TBL] [Abstract][Full Text] [Related]
6. Recombinant human TSH and ablation of post-surgical thyroid remnants in differentiated thyroid cancer: the effect of pre-treatment with furosemide and furosemide plus lithium.
Barbaro D; Grosso M; Boni G; Lapi P; Pasquini C; Orsini P; Turco A; Meucci G; Marzola MC; Berti P; Miccoli P; Mariani G; Rubello D
Eur J Nucl Med Mol Imaging; 2010 Feb; 37(2):242-9. PubMed ID: 19760415
[TBL] [Abstract][Full Text] [Related]
7. Radioiodine lobar ablation as an alternative to completion thyroidectomy in patients with differentiated thyroid cancer.
Bal CS; Kumar A; Pant GS
Nucl Med Commun; 2003 Feb; 24(2):203-8. PubMed ID: 12548045
[TBL] [Abstract][Full Text] [Related]
8. Patients with differentiated thyroid cancer who underwent radioiodine thyroid remnant ablation with low-activity ¹³¹I after either recombinant human TSH or thyroid hormone therapy withdrawal showed the same outcome after a 10-year follow-up.
Molinaro E; Giani C; Agate L; Biagini A; Pieruzzi L; Bianchi F; Brozzi F; Ceccarelli C; Viola D; Piaggi P; Vitti P; Pacini F; Elisei R
J Clin Endocrinol Metab; 2013 Jul; 98(7):2693-700. PubMed ID: 23626005
[TBL] [Abstract][Full Text] [Related]
9. Low versus high radioiodine activity for ablation of the thyroid remnant after thyroidectomy in Han Chinese with low-risk differentiated thyroid cancer.
Lv RB; Wang QG; Liu C; Liu F; Zhao Q; Han JG; Ren DL; Liu B; Li CL
Onco Targets Ther; 2017; 10():4051-4057. PubMed ID: 28860813
[TBL] [Abstract][Full Text] [Related]
10. Impact of early vs late postoperative radioiodine remnant ablation on final outcome in patients with low-risk well-differentiated thyroid cancer.
Tsirona S; Vlassopoulou V; Tzanela M; Rondogianni P; Ioannidis G; Vassilopoulos C; Botoula E; Trivizas P; Datseris I; Tsagarakis S
Clin Endocrinol (Oxf); 2014 Mar; 80(3):459-63. PubMed ID: 23895145
[TBL] [Abstract][Full Text] [Related]
11. Is radioiodine ablation with 1.1 GBq (30 mCi)
Ilera V; Califano I; Cavallo A; Faure E; Vázquez A; Pitoia F;
Endocrine; 2023 Jun; 80(3):606-611. PubMed ID: 36988853
[TBL] [Abstract][Full Text] [Related]
12. [Differentiated thyroid carcinoma--how to improve the long-term results? Twenty-five-year outcomes of 850 patients].
Melliere D; Hindie E; Becquemin JP; Desgranges P; Allaire E; Geachan E
Bull Acad Natl Med; 2006 Jan; 190(1):89-106; discussion 106-9. PubMed ID: 16878448
[TBL] [Abstract][Full Text] [Related]
13. The role of technetium-99m methoxyisobutylisonitrile scintigraphy in the planning of therapy and follow-up of patients with differentiated thyroid carcinoma after surgery.
Rubello D; Mazzarotto R; Casara D
Eur J Nucl Med; 2000 Apr; 27(4):431-40. PubMed ID: 10805117
[TBL] [Abstract][Full Text] [Related]
14. Treatment for microcarcinoma of the thyroid--clinical experience.
Küçük NO; Tari P; Tokmak E; Aras G
Clin Nucl Med; 2007 Apr; 32(4):279-81. PubMed ID: 17413573
[TBL] [Abstract][Full Text] [Related]
15. Radioiodine dose for remnant ablation in differentiated thyroid carcinoma: a randomized clinical trial in 509 patients.
Bal CS; Kumar A; Pant GS
J Clin Endocrinol Metab; 2004 Apr; 89(4):1666-73. PubMed ID: 15070929
[TBL] [Abstract][Full Text] [Related]
16. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer.
Mazzaferri EL; Jhiang SM
Am J Med; 1994 Nov; 97(5):418-28. PubMed ID: 7977430
[TBL] [Abstract][Full Text] [Related]
17. Association between residual thyroid carcinoma and diffuse hepatic uptake of 131I following radioiodine ablation in postoperative total thyroidectomy patients.
Tatar FA; Morita E; Ituarte PH; Cavalieri RR; Duh QY; Price DC; Siperstein AE; Clark OH
World J Surg; 2001 Jun; 25(6):718-22. PubMed ID: 11376405
[TBL] [Abstract][Full Text] [Related]
18. Fractionated dosage of radioiodine for the ablation of low-risk differentiated thyroid cancer has no impact on survival.
Woliński K; Czepczyński R; Stangierski A; Trojanowski M; Rewaj-Łosyk M; Ziemnicka K; Bączyk M; Dyzmann-Sroka A; Ruchała M
Endokrynol Pol; 2018; 69(3):230-234. PubMed ID: 29504625
[TBL] [Abstract][Full Text] [Related]
19. Comparison of 800 and 3700 MBq iodine-131 for the postoperative ablation of thyroid remnant in patients with low-risk differentiated thyroid cancer.
Caglar M; Bozkurt FM; Akca CK; Vargol SE; Bayraktar M; Ugur O; Karaağaoğlu E
Nucl Med Commun; 2012 Mar; 33(3):268-74. PubMed ID: 22205241
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of Reduced Radioiodine Activity for Thyroid Remnant Ablation after Total Thyroidectomy in Patients with Low to Intermediate Risk Differentiated Thyroid Carcinoma.
Todica A; Haidvogl S; Fendler WP; Ilhan H; Rominger A; Haug AR; Bartenstein P; Lehner S
Nuklearmedizin; 2017; 56(6):211-218. PubMed ID: 29533416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
